The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
about
Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium RetentionPPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintyRescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mousePharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Risk of fracture with thiazolidinediones: an individual patient data meta-analysis.Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data.Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus.A randomized trial of therapies for type 2 diabetes and coronary artery diseaseTherapeutic interventions and oxidative stress in diabetesPPARγ in head and neck cancer preventionHigh-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazoneLaboratory evaluation of a new lateral-flow-based point-of-care rapid test for assessment of chronic systemic inflammation.Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin.Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus.Pharmacological and non-pharmacological interventions to influence adipose tissue function.Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?Semantic MEDLINE for discovery browsing: using semantic predications and the literature-based discovery paradigm to elucidate a mechanism for the obesity paradox.Downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery diseaseEffect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.PPARγ ligands regulate NADPH oxidase, eNOS, and barrier function in the lung following chronic alcohol ingestionThiazolidinediones and Risk of Long-Term Dialysis in Diabetic Patients with Advanced Chronic Kidney Disease: A Nationwide Cohort Study.Risk of fracture with thiazolidinediones: disease or drugs?Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study.Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistanceTranscriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-gamma: Therapeutic Implications for Cardiovascular Diseases.Pioglitazone in clinical practice: where are we now?Should We Use PPAR Agonists to Reduce Cardiovascular Risk?PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.Pioglitazone attenuates valvular calcification induced by hypercholesterolemia.PPARgamma Agonists: Potential as Therapeutics for Neovascular RetinopathiesRosiglitazone attenuates NF-κB-mediated Nox4 upregulation in hyperglycemia-activated endothelial cellsPeroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectivesGlucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trialSGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
P2860
Q26851905-E0AC41D6-E3E4-4D80-9AF3-3758FBE42BA9Q27024799-80AA3402-0E70-4571-A0E0-7B47A910F050Q27310125-37FB2C89-AD79-4A3F-A0F9-FFB8EC79E8D0Q30249371-E55D6475-5F91-4917-A016-4F151E92A32BQ30611122-EA15CF55-1D01-4942-A62F-8AAFAABAA13EQ30625765-046F808F-42B1-45CF-864E-A37643077E2DQ33590082-77E198B6-F743-4865-93BF-55E78C8D2B2BQ33827504-E329BE7A-1A6E-485B-B262-C1C1BC9919B9Q33870395-A6F1A954-1412-4E2A-AD44-23132FC4EC49Q33896090-9591A714-4C96-416F-B67D-788A412C566EQ33979763-73AB6488-12AC-4681-91DD-8A3F1D3A9FE6Q33979779-899803A6-CAB1-493C-B8F8-1868A272FB0AQ34113354-8DE2830A-EA4C-4C6F-8164-3D231E772BD5Q34154550-15CC6886-0A20-458C-A4B4-94CE7F458E92Q34212735-F92DF4F5-2040-47A0-BBE1-10E504F2FE69Q34315432-E0C3E102-FC0D-4533-A16D-4CF7E18D2FCBQ34398065-3B951447-DB8A-412A-86AD-6C8B5078D7E4Q34541875-EA57DA7C-9C23-47EA-AAB6-07D81FA83298Q34576535-F236CC81-F9F1-4415-BB49-C3BEC06DBFD7Q34774079-30205EEB-B223-49D9-8C8B-7A5CF9AE2ED5Q34897476-9A2BB237-A881-4943-9474-B35A2935602BQ35097849-E0D85E7A-F746-470E-BE20-738A28C6FF8CQ35130917-034389EB-22B5-479E-A9D0-C7AB5F565CBBQ35337177-47FAB571-715B-4375-9C5E-0AF6B1D59905Q35403487-4A691358-054D-457F-A3A4-10C34A820A3BQ35665975-E0D7305D-2B29-4265-988E-DE306CCBDA4CQ35949113-3BB84730-9BD5-4994-A8A1-C80275B82FB7Q36058654-0A9408C8-24D3-48A0-86FA-0C0327F338D5Q36261125-415D9689-FB85-49D1-A65C-6C179C10B358Q36397303-6AC89368-812A-47CF-82E6-D25D39511A8FQ36426782-DEBE6BD8-C5B3-4A40-A485-777215E6606AQ36428100-72AA0DDD-1D47-4209-97CA-AABE6F505508Q36446970-FB59B4F3-0729-4EDC-A1E1-DE8818644944Q36536316-8B0C8A4C-1620-420F-BDCC-4C2CB7EFD48BQ36612212-6674223F-8889-46A4-A5CF-E5678DFA3D63Q36676571-B3CB17E2-DDB8-41CC-A358-1CF29588FA19Q36777447-1CA15EC6-8ACC-4358-ABCE-9AB3FBC7692CQ36812788-F31EC87D-FF3E-4EC5-86EE-6CBC84F119F7Q36820255-7C04B5E6-B892-4613-8FFF-BBCD7D74BF7FQ36820604-DC36B85B-94EB-4F1D-B7DF-FA296EE5DDAC
P2860
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The effect of pioglitazone on ...... ROactive (PROactive 05) Study.
@ast
The effect of pioglitazone on ...... ROactive (PROactive 05) Study.
@en
The effect of pioglitazone on ...... ROactive (PROactive 05) Study.
@nl
type
label
The effect of pioglitazone on ...... ROactive (PROactive 05) Study.
@ast
The effect of pioglitazone on ...... ROactive (PROactive 05) Study.
@en
The effect of pioglitazone on ...... ROactive (PROactive 05) Study.
@nl
prefLabel
The effect of pioglitazone on ...... ROactive (PROactive 05) Study.
@ast
The effect of pioglitazone on ...... ROactive (PROactive 05) Study.
@en
The effect of pioglitazone on ...... ROactive (PROactive 05) Study.
@nl
P2093
P921
P1476
The effect of pioglitazone on ...... ROactive (PROactive 05) Study.
@en
P2093
Allan M Skene
Bernard Charbonnel
Erland Erdmann
Ian K Moules
John A Dormandy
Massimo Massi-Benedetti
PROactive Investigators
P304
P356
10.1016/J.JACC.2006.12.048
P407
P577
2007-04-16T00:00:00Z